Wednesday, November 25, 2009

Avastin Filed For Broader Breast Cancer Label In Europe For Use In Combination With Standard Chemotherapies

Roche announced today that they have filed to extend the current European label of Avastin (bevacizumab) in patients with metastatic breast cancer to allow its use in combination with a broader range of standard chemotherapies. Avastin is currently licensed in the EU as first-line treatment for patients with metastatic breast cancer in combination with paclitaxel or docetaxel.

The details can be read here.

No comments: